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Clinical and epidemiological introduction
Sudden  infant  death  syndrome  (SIDS)  is  the  leading 
cause  of  postneonatal  infant  death,  and  represents  the 
third leading cause of infant mortality overall in the USA 
[1]. As defined by Willinger et al. in 1991 [2], SIDS is 
described as the sudden death of an infant under 1 year 
of age which remains unexplained after a thorough case 
investigation,  including  performance  of  a  complete 
autopsy, examination of the death scene, and review of 
clinical history. SIDS pathogenesis has been understood 
through a ‘triple risk hypothesis’. This argues that SIDS 
results  from  a  convergence  of  three  overlapping  risk 
factors: (1) a vulnerable infant, (2) a critical development 
period, and (3) an exogenous stressor(s) [3]. An infant 
will only succumb to SIDS if and when all three over­
lapping  factors  exist  and  converge.  Thus,  the  inherent 
vulnerability of an infant will lie dormant until a crucial 
developmental period when the infant is then presented 
with the exogenous stressor.
Nearly  two  decades  ago,  the  1994  ‘Back  to  Sleep’ 
campaign  from  the  National  Institute  of  Child  Health 
and  Human  Development  in  the  USA  targeted  such 
exogenous  stressors  as  prone  sleep,  and  reduced  SIDS 
rates by more than 50% from 1.2 per 1,000 live births in 
1992  to  0.55  per  1,000  live  births  in  2006,  similar  to 
reductions  seen  in  Canada  and  many  other  countries 
[4,5]. However, despite these efforts, over 2,200 infants 
died  of  SIDS  in  2004,  and  it  appears  that  the  recently 
witnessed  reductions  in  deaths  are  diminishing  [4]. 
Today, SIDS remains one of the leading causes of death 
for  infants  between  1  month  and  1  year  in  developed 
countries [6], and current data suggest that approximately 
60%  to  80%  of  deaths  under  the  age  of  1  year  remain 
autopsy negative [7,8].
Among  developed  countries,  SIDS  rates  vary  widely 
[6],  and  ethnic­specific  disparities  in  rates  have  been 
noted. For example, SIDS rates are approximately twice 
as  high  among  infants  born  to  African  American  or 
American Indian mothers as compared with Caucasian 
mothers in the USA [5], and increases in SIDS risk are 
also  seen  for  the  Maoris  in  New  Zealand,  Aboriginal 
Australians  [6],  and  those  of  mixed  ancestry  in  Cape 
Town, South Africa [9]. In part, these data suggest that 
there  may  be  genetic  determinants  of  the  ‘vulnerable 
infant,’  and  many  studies  have  examined  the  genetic 
makeup of SIDS cases.
The  first  such  report  of  a  ‘genetic  autopsy’  was 
published by Weinberg and Purdy in Nature in 1970 [10]. 
They  performed  karyotype  analysis  on  17  SIDS  cases, 
with 10 out of 11 available karyotypes declared abnormal 
compared with none in the living control group, suggesting 
a  potential  genetic  link.  Monumental  technological 
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© 2010 BioMed Central Ltdadvances  in  genomic  research,  coupled  with  genetic/
mutational analyses of large SIDS cohorts, have increased 
substantially our knowledge of the genetic risks for SIDS. 
This review systematically focuses on the literature that 
has specifically evaluated genetic factors in SIDS victims.
Using  PubMed  as  our  search  engine,  with  the  key 
phrase ‘sudden infant death’, and ‘gene’, ‘polymorphism’, 
or ‘mutation’, we identified 94 investigations of genetic 
variation  in  population­based  SIDS  cohorts  between 
1989 and 2010. We did not include case reports or other 
reviews as sources. We excluded three studies based on 
definitions  of  SIDS  contrary  to  accepted  current 
practices. Ninety­one studies remained, with an average 
cohort size of 125 SIDS cases (range 2 to 1,304). The vast 
majority of studies comprised 50 to 200 SIDS cases. In 
defining  their  cohorts,  many  used  the  standard  1991 
definition by Willinger et al., while others relied on more 
regional definitions that were more or less similar, such 
as  the  Nordic  criteria  [11]  or  the  current  San  Diego 
definition [12]. Unfortunately, one­third of studies did 
not explicitly define their criteria, and this may affect the 
potential  strength  of  reported  associations  with  true 
SIDS  cases.  Eighty­nine  percent  of  the  cohort  studies 
examined genes that can be divided into five potential 
SIDS­predisposing  pathways:  central  nervous  system 
pathways,  cardiac  channelopathies,  immune 
dysfunction, metabolism/energy pathways, and nicotine 
response. A summary is shown in Table 1. This review 
will  examine  the  genetic  links  associated  with  SIDS 
involving these particular pathways. In addition, we will 
explore  the  involvement  of  genomic  copy  number 
variations as a molecular basis for some SIDS, some new 
technologies that may assist in the advancement of our 
current molecular pathogenic knowledge of SIDS, and 
what  the  future  holds  for  prenatal  and  postnatal  risk 
assessment for SIDS.
Central nervous system pathways
A  number  of  recent  reviews  have  summarized  the 
current  data  implicating  central  nervous  system  dys­
function  in  SIDS,  with  a  particular  focus  on  the 
autonomic nervous system [13,14]. Such dysfunction can 
result  in  unresponsiveness  to  asphyxia,  progressing  to 
hypoxic coma and death [1]. It is therefore not surprising 
that  a  number  of  genomic  factors  in  the  autonomic 
nervous  system,  and  particularly  within  serotonergic 
signaling pathways, have been linked with increased SIDS 
risk. Our examination of the literature revealed 20 studies 
examining  the  link  between  nervous  system  genetic 
variants and SIDS.
The 5-HT signaling pathway
Fourteen studies have focused on genetic variation within 
the  5­HT  signaling  pathway.  The  most  highly  studied 
correlation has involved the 5-HTT gene, which encodes 
the  serotonin  transporter.  A  common  variation  within 
the promoter region involves varying copies of a 20 to 
23 base pair repeat unit: a shorter allele of 14 copies, a 
long allele of 16 copies, or a rare extra­long allele of 18 to 
20  copies  [14,15].  A  longer  allele  is  associated  with  a 
more  effective  promoter  and  therefore  reduced  5­HT 
concen  trations at nerve endings [4,16], and reductions in 
5­HT concentrations have been reported in SIDS cases of 
various ethnicities [17­20]. Narita et al. [15] first reported 
differences  in  both  genotype  distribution  and  allele 
frequency in a small study involving 27 Japanese SIDS 
cases and age­matched controls, with the long (L) and 
extra­long alleles occurring more frequently in SIDS than 
in controls. Six subsequent cohort studies have attempted 
to verify the association in various ethnicities, with three 
reporting positive associations in cohorts of 20 Italian, 28 
Italian,  and  87  American­Caucasian  and  African­
American  SIDS  cases  [21­23],  while  three  studies 
reported no asso  ciation in cohorts of 31 SIDS of various 
ethnicities,  145  Swiss  SIDS  cases,  and  163  Norwegian 
SIDS cases [17,24,25].
In addition, two studies investigated the association of 
a polymorphic variable number tandem repeat (VNTR) 
in  intron  2  of  the  5-HTT  gene  containing  9,  10,  or 
12 copies of a 16 to 17 base pair repeat sequence with 
SIDS, with 12 copies increasing expression [26]. Weese­
Mayer et al. [27] found in 90 SIDS cases an increase in 
Table 1. Summary of SIDS-associated gene studies and implicated genes
    Studies with positive     
  Total number  genotype association  Mean cohort  Genes independently verified 
Pathway  of studies  or mutations implicated  size (range)  [references]
Central nervous system  20  13  85 (20 to 172)  5-HTT [15,21-23]
Cardiac channelopathies  16  13  141 (6 to 292)  KCNQ1, KCNH2, SCN5A [50,52,101,102]
Immune dysfunction  20  10  103 (16 to 250)  IL6, IL10, C4A, C4B [70,71,73,75,77,82,83]
Metabolism/energy  23  5  178 (2 to 1304)  Mitochondrial D-loop, MCAD [85,86,90,91]
Nicotine response  2  1  106, 159  None
SIDS, sudden infant death syndrome.
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American  SIDS  cases  (P  =  0.002)  but  not  Caucasian 
(P  =  0.117)  subgroups  when  compared  with  controls 
matched for ethnicity and gender. These findings high­
light  potential  ethnic  differences  in  genetic  variation 
within the 5-HTT gene, and may explain the failure of 
some  cohort  studies  to  replicate  the  promoter  variant 
findings. Nonnis Marzano et al. [22] also reported the 
L­12 haplotype as nearly twofold higher among 20 Italian 
SIDS cases (44.5%) compared with 150 Italian controls 
(23.4%). However, this was not statistically significant.
Filonzi et al. [28] reported in 20 SIDS cases a highly 
significant interaction between the 5-HTT L allele and 
polymorphisms  in  the  gene  encoding  the  neuro  trans­
mitter inactivator monamine oxidase A (MAOA), suggest­
ing the two genotypes act synergistically in modulating 
SIDS  risk.  Two  cohort  studies  have  also  examined  the 
serotonin  receptor  HTR1A  and  HTR2A  genes,  respec­
tively, but did not report any positive associations [29,30]. 
Lastly, Rand et al. [31] reported an association with an 
intronic variant in the mouse ortholog of the fifth Ewing 
variant gene (FEV), which is critical for 5­HT neuronal 
development,  in  a  cohort  of  96  SIDS  cases  compared 
with controls, and in the African­American SIDS subset 
versus Caucasian SIDS. However, this association failed 
to replicate in a slightly smaller cohort of 78 cases [32].
Early autonomic nervous system development genes
Weese­Mayer et al. [33] examined eight genes involved in 
early  development  of  the  autonomic  nervous  system: 
BMP2, MASH1, PHOX2a, RET, ECE1, EDN1, TLX3, and 
EN1.  Interestingly,  they  reported  11  protein­changing 
rare  mutations  in  14  of  92  SIDS  cases  within  the 
PHOX2a, RET, ECE1, TLX3, and EN1 genes [33]. Only 
the  mutation  in  TLX3  was  present  in  the  92  matched 
controls.  Further,  African­American  infants  accounted 
for ten of these mutations in SIDS cases and two control 
subjects; the authors claimed that this suggests an ethnic 
component  [33].  Unfortunately,  whether  any  of  these 
mutations impart functional protein changes to impact 
neuronal  development  and  contribute  to  autonomic 
nervous system instability remains unstudied, and these 
genes/mutations have not been independently validated 
in other cohorts.
Rand et al. [34] demonstrated a positive association in 
genotype distributions for a common SNP in intron 2 of 
the PHOX2b early autonomic function gene in 91 SIDS 
cases  versus  matched  controls  over  the  total  data  set 
(P = 0.0009) and specifically in the Caucasian SIDS cases 
versus controls (P = 0.005). In addition, eight polymor­
phisms  (two  amino  acid  altering)  located  in  the  third 
exon  of  the  PHOX2B  gene  occurred  more  frequently 
among SIDS cases (34 occurrences observed in 27 out of 
91 cases) than controls (19 occurrences observed in 16 
out of 91 controls, P = 0.01). This frequency was pre­
served  among  both  Caucasian  and  African­American 
subgroups [34]. Kijima et al. also examined the PHOX2B 
gene in 23 Japanese SIDS cases for mutations associated 
with  the  congenital  central  hypoventilation  syndrome, 
also  similarly  characterized  by  autonomic  dysfunction 
[35,36].  They  reported  three  variants  not  reported  by 
Rand et al. but did not clarify if these were found in cases 
or  controls,  nor  did  they  report  the  frequency  of  the 
polymorphisms reported by Rand et al. [35].
Lastly,  positive  associations  have  been  seen:  (1)  with 
the apolipoprotein E e4 allele (167 Scottish SIDS), which 
plays a role in neuronal repair and protection, and has 
been  implicated  previously  in  Alzheimer’s  disease;  (2) 
with an intronic variant in the tyrosine hydroxylase gene 
(172  German  SIDS  cases),  which  plays  a  role  in 
neurotransmitter production; and (3) in a small cohort of 
17 African­American SIDS cases, with the gene encoding 
pituitary adenylate­cyclase­activating polypeptide, which 
plays a role in central respiration [37­39].
Cardiac channelopathies
The  abundance  of  evidence  for  the  link  between  SIDS 
and  cardiac  channelopathies  has  been  well  reviewed 
recently  [40].  Briefly,  heritable  cardiac  channelopathies 
arise  from  mutations  within  genes  that  encode  crucial 
ion channels or ion channel regulators that when func­
tionally  perturbed  cause  potentially  lethal  arrhythmo­
genic  ‘sudden  death’  disorders,  such  as  long  QT 
syndrome (LQTS), Brugada syndrome, and catecholami­
nergic polymorphic ventricular tachycardia, that leave no 
detectible clues at autopsy.
Over 30 years ago, both Schwartz [41] and Maron et al. 
[42] proposed a link between LQTS and SIDS, and this 
was the first such channelopathy to be implicated in this 
syndrome. LQTS affects approximately 1 in 2,500 indi­
viduals [43], often evidenced by its electrocardiographic 
hallmark of QT interval prolongation, and can present 
clinically with syncope, seizures, or sudden death due to 
its trademark arrhythmia torsades de pointes [44]. The 
1976 hypothesis was advanced in 1998 by the publication 
of  a  monumental  19­year  prospective  study  of  over 
34,000 infants, recording electrocardiograms on the third 
or fourth day of life [45]. Significantly, 12 of the 24 infants 
that went on to die of SIDS had a QTc exceeding 440 ms 
recorded  during  the  first  week  of  life,  a  QTc  value 
reflecting the 97.5th percentile for the entire population 
of 3­ and 4­day­old infants. Two years later, Schwartz et 
al. [46] extended the chain of evidence towards a primary 
channelopathic  cause  for  some  cases  of  SIDS  with  a 
resuscitated sudden death during the first year of life in 
an infant later diagnosed with LQTS.
Since  this  proof  of  principle  case  report,  16  cohort 
studies from 2001 to 2010 have examined the spectrum 
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Overall,  13  out  of  16  studies  positively  associated 
channel  opathies  with  SIDS  cases,  with  9  studies 
identifying  novel  SIDS­associated  mutations  in  genes 
implicated in the cardiac channelopathies including long 
QT  syndrome,  as  well  as  two  other  channelopathies, 
Brugada syndrome and catecholaminergic polymorphic 
ventricular tachycardia, which can also result in sudden 
cardiac  death  [47­49].  Of  note,  10  out  of  16  studies 
utilized  electrophysiological  function  studies  either  in 
HEK cells or cardiac myocytes in the same or subsequent 
publications  to  validate  the  pathogenic  nature  of  the 
putative SIDS­associated mutations that were identified.
Our research program performed the first systematic 
postmortem  genetic  testing  of  the  SCN5A­encoded 
Nav1.5  cardiac  sodium  channel  in  a  population­based 
cohort  of  SIDS.  Two  missense  mutations,  A997S  and 
R1826H,  were  discovered  in  two  of  the  58  Caucasian 
SIDS cases and were absent in 800 reference alleles. Both 
mutations  demonstrated  delayed  channel  inactivation 
kinetics and a two­ to threefold increase in late sodium 
current [50]. Since this first study, we have now identified 
putative  LQTS­causing  mutations  in  3  of  58  (5.2%,  2 
SCN5A and 1 KCNH2) SIDS cases in white infants, and 1 
of 34 (2.9%, 1 KCNQ1) SIDS cases in black infants [51]. 
However, the biophysical effects of the latter two variants 
were not examined. Importantly, in these studies, only 
those  variants  that  were  deemed  primary  pathogenic 
mutations  (not  seen  in  controls)  were  reported  rather 
than rare polymorphisms seen in both cases and controls 
that  may  or  may  not  contribute  towards  a  significant 
underlying risk for sudden death during infancy.
Arnestad  et  al.  [52]  replicated  this  association  in  a 
separate  cohort  of  201  Norwegian  SIDS  cases, 
examining  seven  LQTS­susceptibility  genes  and 
reporting a 9.5% (19 of 201) prevalence of functionally 
significant  rare  genetic  variants.  The  vast  majority  of 
these  mutations  were  identified  in  the  three  major 
LQTS­susceptibility  genes:  KCNQ1,  KCNH2,  and 
SCN5A. A subsequent study demonstrated that five of 
the eight variants within SCN5A had increased LQT3­
like late sodium current. The other three also displayed 
increased  late  current  under  various  exogenous 
stressors [53]. Some of the potassium channel variants 
also displayed functional impairment [54].
Overall, these findings indicate that (1) approximately 
10%  of  SIDS  may  emanate  from  LQTS­causing  muta­
tions,  and  (2)  the  cardiac  sodium  channel  assumes  a 
prominent  position  in  channelopathic  SIDS.  While 
mutations  in  SCN5A  account  for  only  5%  to  10%  of 
LQTS, SCN5A comprises half of the rare ‘channelopathic’ 
variants found in the Norwegian cases, and all of these 
had  functional  phenotypes  [52,53].  It  is  interesting  to 
note  that,  to  date,  10  out  of  the  16  studies  identified 
variants either within SCN5A or within genes encoding 
crucial regulators of the cardiac sodium channel macro­
molecular  complex,  including  the  genes  encoding 
caveolin­3  (CAV3),  GPD1­L  (GPD1-L),  α1­syntrophin 
(SNTA1), and the sodium channel beta subunits encoded 
by SCN1B, SCN2B, SCN3B and SCN4B [55­58]. Our own 
examination  of  292  SIDS  cases,  including  unpublished 
data, has identified 17 out of 292 SIDS cases with variants 
in the Nav1.5 macromolecular complex that had an in 
vitro channelopathic phenotype [55­58].
Interestingly,  one  study  in  42  SIDS  cases  positively 
correlated SIDS with a SNP in the NOS1AP gene [59], 
which has also been correlated with variation in the QT 
interval [60,61]. In addition, another study examined a 
common polymorphism within the MT-ND1 gene within 
the mitochondrial genome. This polymorphism, T3394C, 
has  been  associated  with  prominent  U  waves  on  the 
electrocardiogram after exercise and episodes of syncopal 
attacks, and is considered a risk factor in LQTS patients 
for malignant arrhythmias [62]. Although that study did 
not  identify  any  association,  there  was  an  association 
within SIDS cases found in the prone sleep position or 
co­sleeping  with  a  parent;  these  are  both  known  risk 
factors for SIDS [62]. The authors hypothesize that such 
environmental  risk  factors  may  have  impacted  the 
vulnerability associated with increased body temperature 
in these SIDS cases [62].
Lastly,  two  independent  studies  have  associated  the 
common  African­American  specific  polymorphism 
S1103Y  in  SCN5A  with  increased  risk  for  SIDS  in  the 
African­American  population  [63,64].  Overall,  these 
relatively large cohort analyses (approximately 200 to 300 
cases) suggest that up to 10% of SIDS may stem from 
cardiac arrhythmias undiagnosed during the first year of 
life. The SCN5A­encoded cardiac sodium channel and its 
macromolecular  complex  play  a  prominent  role  in 
cardiac  ‘channelopathic  SIDS’.  Why  Nav1.5­mediated 
channelopathic  sudden  death  is  particularly  central  to 
channelopathic  death  may  be  due  to  sleep  being  a 
common  trigger  for  arrhythmias  in  both  Brugada 
syndrome and LQT3 [65­67]. However, the mechanisms 
whereby sleep is specifically a trigger in sodium­channel­
mediated arrhythmias remain poorly understood.
Immune dysfunction
There is also compelling evidence for perturbed immune 
responses and/or inflammatory changes in SIDS patho­
genesis  [68,69].  We  identified  20  studies  examining 
various genes encoding proteins involved in modulating 
immune  function  that  examined  the  link  between 
immune deficiency and SIDS. These studies focused on 
either  genotyping  common  polymorphisms  or  looking 
for gene deletions, and only ten of the studies reported 
positive associations. The two most highly studied are 
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encoding  IL­6  and  IL­10,  as  well  as  early  studies  on 
deletions  in  the  complement  pathway  C4  genes.  The 
most  commonly  investigated  IL-10  polymorphisms  in 
SIDS  are  the  promoter  variants  at  positions  ­1082*A, 
­819*T, and ­592*A.
In 2000, Summers et al. [70] reported in a small cohort 
of only 23 cases an increased association of the haplotype 
­1082*A,  ­819*T,  and  ­592*A  (ATA)  with  SIDS,  most 
likely  due  to  the  A  allele  at  the  592  location,  which 
generated a SIDS odds ratio of 3.3 (P = 0.007). In 2003, 
Opdal et al. [71] were unable to replicate this association 
in  a  study  involving  214  cases  of  SIDS  in  Norway. 
However, this may be due to the inclusion in the first 
group of infectious causes of death, as the authors did see 
an association between the ATA haplotype and infants 
that died of infectious causes. However, the same study 
did  implicate  the  IL-10  gene  in  SIDS,  describing  the 
association with SIDS of a short tandem repeat locus, IL­
10G, positioned approximately 4.0 kb 5’ of the trans  crip­
tion start site, and 13 IL­10G alleles spanning from 16 to 
28 CA repeats have been described. The SIDS cases had a 
higher  percentage  of  G21/G22  than  the  controls 
(P = 0.017) [71]. Subsequently, however, Moscovis et al. 
[72]  were  also  unable  to  replicate  the  haplotype  asso­
ciation in 85 cases of SIDS. However, these investi  gators 
only genotyped the ­1082 polymorphism, which was not 
the strongest link in the original study. Korachi et al. [73] 
found an association of the ATA haplotype in 38 British 
SIDS  cases.  In  contrast,  Perskvist  et  al.  in  2008  [74] 
examined 23 cases examining the entire haplotype and 
did not find any association.
Thus,  IL­10  has  not  been  established  definitively  in 
SIDS pathogenesis, with failure to validate and replicate 
initial signals derived from small sample sized cohorts. 
The  association  between  the  short  tandem  repeat  and 
SIDS has not been replicated, and it is clear that future 
research  is  necessary.  Four  studies  have  examined  the 
association of polymorphisms in the IL-6 gene, with two 
positive (25 UK SIDS cases and 19 Caucasian Australian 
SIDS  cases)  and  two  failed  associations  (175  and  204 
Norwegian SIDS cases) [75­78]. Other positive asso  cia­
tions with SIDS have been seen with VEGF (25 UK SIDS), 
and  IL­1α  and  IL­1  receptor  antagonist  genes  (204 
Norwegian  SIDS  cases  and  49  Australian  SIDS  cases, 
respectively), and TNF-α promoter region (204 Norwe­
gian SIDS) [75,79­81]. Deletions of the complement C4A, 
C4B  genes  have  been  demonstrated  in  two  separate 
studies between SIDS cases in Norway that had recent 
infections and complement gene deletions [82,83].
Metabolism/energy pathways
Inborn errors of metabolism account for approximately 
1% to 2% of sudden death during the first year of life [8], 
and the evidence linking energy dysregulation to SIDS 
has  been  described  [14].  Genes  encoding  proteins 
involved in metabolic pathways and energy production 
have been examined frequently in SIDS and, to date, 23 
studies  have  examined  genes  that  encode  for  crucial 
proteins involved in these processes. Thus far, 12 studies 
have  examined  the  role  of  medium­chain  acyl­CoA 
dehydrogenase  (MCAD)  deficiency,  an  inborn  error  in 
metabolism, in SIDS. Phenotypic presentation varies, but 
20% to 25% of patients homozygous for mutations in the 
MCAD gene can present with sudden death [84]. Eleven 
out of twelve genetic studies examined their cohort for 
the frequency of the most common mutation G985A, but 
only  Lundemose  et  al.  [85]  and  Yang  et  al.  [86]  each 
reported one homozygous case in cohorts of 61 and 220 
SIDS  cases,  respectively.  Therefore,  although  MCAD 
deficiency can result in a sudden death during the first 
year of life, it is unlikely that such a death will be given a 
diagnosis  of  SIDS  rather  than  MCAD  deficiency­
associated death.
Cohort examinations of mutations and polymorphisms 
in the aldolase B, glucokinase, and glucose­6­phosphatase 
genes did not report any association with SIDS [87,88]. A 
subsequent  study  by  Forsyth  et  al.  [89]  did  report  an 
association  with  variation  in  the  promoter  of  the 
endoplasmic reticulum glucose­6­phosphate transporter 
G6PT1,  which  is  required  for  hepatic  glucose­6­
phosphatase activity in vivo. In a cohort of 170 Northern 
European SIDS cases, the allele frequency of a C→T at 
position ­259 was significantly higher in term SIDS than 
in preterm SIDS or controls. Luciferase assays demon­
strated  that  the  ­259*T  activity  was  3.2­fold  lower 
(P  <  0.005)  than  that  of  the  wild­type  construct.  In 
addition,  they  correlated  these  findings  to  increased 
latency  (decreased  G6PT1  activity)  of  liver  glucose­6­
phosphatase  activity  from  SIDS  heterozygous  and 
homozygous for the ­259T substitution compared with 
patients homozygous for ­259C (P < 0.0001) [89].
Lastly, five studies have examined various parts of the 
mitochondrial  genome  for  variation  in  SIDS  cohorts. 
Two separate studies, one including only nine German 
SIDS cases, and one including a much larger cohort of 
158  Norwegian  SIDS  cases,  identified  variation  within 
the  most  polymorphic  region  of  the  mitochondrial 
genome, the so­called displacement loop [90]. The German 
study  correlated  SIDS  cases  with  a  specific  haplotype 
within  the  displacement  loop  [90],  whereas  the 
Norwegian study identified four mutations of unknown 
significance, while no controls were mutated [91].
Nicotine response
While the associations between exogenous exposure to 
nicotine  and  SIDS  are  clear  and  have  been  reviewed 
extensively [14,92], we have identified only two studies 
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SIDS  infants  and  defects  in  nicotine  metabolizing 
enzymes. Rand et al. [93] explored associations between 
SIDS  and  the  nicotine  metabolizing  enzyme  genes 
GSTT1 and CYP1A1 in 106 Norwegian SIDS, but did not 
report any associations. Poetsch et al. [94] investigated 
polymorphisms  in  the  nicotine  metabolizing  enzyme 
gene  FMO3,  which  encodes  flavin­monooxygenase  3, 
where genetic variants have been shown to impair nico­
tine metabolism. The common polymorphism 472G>A 
results in the amino acid change E158K. The homozygous 
AA genotype was over­represented in 159 German SIDS 
cases compared with controls, and interestingly was also 
over­represented in SIDS cases whose mothers reported 
heavy  smoking  (10  cigarettes  or  more  per  day  during 
pregnancy) compared with SIDS victims whose mothers 
did not smoke [94]. This study highlights the potential 
interaction between genetic vulnerability (polymorphism 
that may impair nicotine metabolism) and an environ­
mental insult (cigarette exposure) in SIDS pathogenesis.
Copy number variation, new technology and SIDS
The notion that cytogenetic abnormalities such as large 
copy number variations (CNVs) may play a role in SIDS 
has existed since the 1970s. Beyond the Nature paper by 
Weinberg  and  Purdy,  Sutherland  et  al.  [95]  performed 
pediatric  postmortems  on  Australian  children  via 
chromo  some banding during a 6­year period. However, 
only two of the 135 SIDS cases examined in that study 
had abnormal karyotypes, which did not differ from rates 
in unselected live children. In contrast, Toruner et al. [96] 
recently  reported  the  first  systematic  examination  of  a 
group of 27 SIDS/unclassified sudden infant death cases 
and  their  families  for  large  CNVs.  The  authors  used 
array­based comparative genomic hybridization to detect 
four large duplications in three SIDS cases. One victim 
had a duplication of approximately 3 Mb on chromosome 
8q and a 4.4 Mb deletion on chromosome 22q13.3. Another 
SIDS case had a 240 kb deletion in chromosome 6, and a 
third had a 1.9 Mb deletion, also in chromosome 6.
The study highlighted the recently appreciated role that 
CNVs can play in complex disease processes. CNVs are a 
collection of structural variations within the genome that 
range from kilobases to megabases and are not detectable 
by  conventional  chromosomal  banding  [97].  Recent 
studies have identified 11,700 CNVs in over 1,000 genes 
that account for 13% of the genome [97]. Although they 
can certainly be inherited, it is thought that large de novo 
CNVs are more likely to cause disease. CNVs have been 
implicated in a myriad of diseases, including autism and 
schizophrenia, where CNV identifications have pointed 
to new gene loci of disease [97]. However, the extent to 
which CNVs are involved in SIDS is far from clear, given 
the small sample size of the current study. In addition to 
providing the causative genetic vulnerability, CNVs may 
also unmask genetic vulnerability caused by a mutation 
or polymorphism in a specific gene whose effect may be 
autosomal recessive in nature but manifests due to the 
deletion of the normal allele.
New developments in technology for genome explora­
tion have improved our ability to probe deeper into the 
‘SIDS genome’. Methods thus far used in genetic analyses 
of SIDS have included a combination of denaturing high­
performance  liquid  chromatography,  ‘first­generation’ 
direct  Sanger  sequencing,  and  genotyping  for  known 
SNPs using allele­specific probes. Such approaches will 
continue to identify novel SNP associations or mutations 
within  known  genes  using  a  candidate  gene  approach. 
However, a limitation of this approach is the inability to 
identify new genes in novel pathways that potentially play 
a  role  in  this  complex  disease.  Ideally,  combining  this 
approach  with  the  more  global  approach  allowed  by 
novel  technology  will  most  quickly  help  us  to  develop 
clearer genomic profile(s) of the genetically ‘vulnerable’ 
infant.  Such  approaches  include  the  aforementioned 
array­comparative  genomic  hybridization  technique, 
newer generations of SNP arrays, and multiplex ligation­
dependent probe amplification, which are all optimally 
suited  to  detect  multiple  SNPs  as  well  as  CNVs.  In 
addition,  next­generation  sequencing  technologies  now 
provide a means of deep sequencing as sequencing costs 
continue  to  decrease  with  increased  sequencing  capa­
bilities,  and  soon  genome  assembly  comparisons  will 
potentially  allow  a  richer  comparison  between  SIDS 
cases and controls, circumventing the problem of small 
cohort size that has plagued SIDS research during the 
genome­wide  association  study  or  ‘GWAS’  era.  Lastly, 
with  the  completion  of  the  1,000  Genomes/Exomes 
Project,  scientists  will  be  able  to  examine  the  areas 
around  SIDS­associated  SNPs  and  potentially  identify 
novel or rare functional variants in linkage disequilibrium 
with those SNPs, thereby allowing scientists to eventually 
identify novel SIDS­causative variants and genes [98].
Impact on pre- and postnatal risk assessment
Finally, what does the future hold for pre­ and postnatal 
risk assessment using this newfound genetic information? 
Given  the  myriad  of  pathways  implicated  by  genomic 
studies, the best way forward is difficult to navigate. For 
example,  although  it  is  clear  from  the  literature  that 
seronergic, channelopathic, immunologic, metabolic, and 
nicotinic mechanisms play a potential role in modulating 
SIDS  risk  to  varying  degrees,  it  is  still  unclear  which 
combination  of  variants  creates  the  milieu  that 
reasonably predicts SIDS risk. Is a predisposing SNP in 
IL-10  enough  of  a  genetic  vulnerability  to  suggest 
preventative measures? How does the risk change with 
the addition of the S1103Y­SCN5A polymorphism and 
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date, all studies have focused exclusively on a particular 
pathway,  with  over  two­thirds  of  the  studies  focusing 
exclusively  on  one  gene.  Thus,  it  is  unknown  to  what 
extent  ‘immunologic’  SIDS  and  ‘channelopathic’  SIDS 
overlaps  with  ‘serotonergic’  SIDS.  In  addition,  one­
quarter of the cohorts numbered under 50 cases, and the 
cases also varied significantly ethnically, so to what extent 
such studies will ‘generalize’ to the global population of 
‘at risk’ infants remains to be seen. In fact, only approxi­
mately 7% of the studies examined here included some of 
the more ‘at risk’ ethnicities, such as African American.
Also,  how  would  one  approach  the  potential  of  a 
genetic  test  to  identify  at­risk  infants?  Using  as  an 
example the cardiac channelopathies, several difficulties 
with  universal  screening  immediately  surface.  For 
example,  the  observation  that  2%  of  otherwise  healthy 
Caucasian  adult  volunteers  nevertheless  host  a  rare 
variant  in  SCN5A,  the  gene  most  often  implicated  in 
channelopathic  SIDS,  is  quite  problematic  for 
interpreting  the  significance  of  a  universal  genetic  test 
result  [99,100].  Though  current  data  are  beginning  to 
elucidate which mutations are functionally relevant and 
indeed pathogenic, this complex issue of distinguishing 
true mutations from so­called background genetic noise 
must be deciphered before such a genetic test could be 
implemented effectively and universally among infants. It 
is reasonable to suggest that similar issues arise for the 
other pathways described herein. For many of the cohort 
studies examined, especially those outside the channel  o­
pathies  where  the  functional  readouts  are  much  less 
defined,  it  is  unclear  what  the  physiologic  effects  of 
implicated SNPs and variants are, and more studies are 
needed to explore in vivo effects of variation within these 
pathways. To be sure, there is NO role or justification for 
universal infant genetic testing for identifying the ‘at­risk’ 
infant at this time.
Meanwhile, perhaps the most immediate way forward 
is the implementation of new ‘standards of care’ for the 
cases and families of SIDS. It is clear from our review of 
the literature that it is reasonable to explore and pursue 
postmortem genetic testing/genotyping of a SIDS victim 
as part of the infant’s comprehensive autopsy. However, it 
is  critical  to  bear  in  mind  that  the  yield  of  a  cardiac 
channel­centric molecular autopsy of a SIDS case is going 
to be around 10% to 15% and the potential ‘background’ 
genetic noise rate for the genes surveyed could be as high 
as 5% in Caucasians and even higher in non­Caucasians. 
Therefore, a ‘positive’ genetic test result must be scruti­
nized  carefully  before  concluding  that  the  infant’s 
pathogenic substrate for his/her death has been estab­
lished  beyond  a  reasonable  doubt.  For  channelopathic 
SIDS,  the  anonymized  study  design  of  several  SIDS 
investigations  precludes  the  knowledge  of  the  relative 
percentage of familial channel mutations versus sporadic 
mutations.  However,  taking  these  findings  together,  it 
seems quite reasonable to recommend a 12­lead electro­
cardiogram  for  first­degree  relatives  of  a  SIDS  case  to 
further  investigate  the  possibility  of  familial  LQTS.  In 
total, the future is bright for SIDS genomic research, and 
with the pathways now well­established, more research 
into  the  mechanisms  by  which  genetic  variation 
predisposes to sudden death is necessary to fully bring 
these bench­side discoveries back to the crib to prevent 
such tragic deaths.
Conclusions
Many  cohort  studies  with  a  wide  range  of  sizes  and 
ethnicities have examined the genetic factors that may 
predispose  an  infant  to  SIDS.  Given  the  magnitude  of 
data on various genes, this review has examined syste  m­
atically the evidence for various gene­encoded proteins 
and  their  signaling  pathways  and  their  contri  bution  to 
SIDS risk. While genetic risk factors are clearly present, 
more  work  is  needed  to  examine  the  mechanisms  for 
how  individual  genetic  factors  truly  create  ‘infant 
vulnerability’. In addition, work is needed to explore how 
these  factors  can  combine  to  create  the  ‘genomic 
fingerprint’  of  SIDS  predisposition.  It  is  our  hope  that 
new technologies will allow such knowledge to be quickly 
ascertained in the quest to eradicate these tragic deaths.
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